RHYTHM PHARMACEUTICALS, INC.
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
Rhythm Pharmaceuticals develops and markets treatments for rare genetic obesity disorders, including its approved drug setmelanotide, which targets deficiencies in the MC4R pathway that regulates hunger and energy balance.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Meeker David PPresident and CEO | Sell | $3.15M | 30,746at $102.35 | Sep 14, 2026 |
| Meeker David PPresident and CEO | Sell | $900K | 8,698at $103.43 | Sep 14, 2026 |
| Meeker David PPresident and CEO | Sell | $655K | 6,439at $101.75 | Sep 14, 2026 |
| Meeker David PPresident and CEO | Sell | $242K | 2,300at $105.19 | Sep 14, 2026 |
| Meeker David PPresident and CEO | Sell | $190K | 1,817at $104.55 | Sep 14, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable RYTM activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.